title: [Ifosfamide, cisplatin, adriamycin combination chemotherapy in gynecologic cancer].
abstract: Thirteen patients with gynecologic cancer were treated with ifosfamide (2 g X 5), cisplatin (70 mg/m2) and adriamycin (20 mg/m2) combination chemotherapy. The response rate of 7 evaluable patients was 43%, with a median duration of survival of 14 months. Six patients with non-measurable disease are currently free from disease with a median duration of survival of 18 months. This combination caused reversible myelosuppression. No hemorrhagic cystitis was observed.
authors: Dept. of Gynecology, Center for Adult Diseases, Osaka.
authors: M
authors: M
authors: Sawada
authors: M
authors: M
authors: Inagaki
authors: Y
authors: Y
authors: Hirota
authors: J
authors: J
authors: Hongo
authors: M
authors: M
authors: Ozaki
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007262:Infusions, Intravenous; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy*
chemical_list: D004317:Doxorubicin; D002945:Cisplatin; D007069:Ifosfamide